Open AccessPredominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner
Author(s) -
Liat Izhak,
Gizi Wildbaum,
Uri Weinberg,
Yuval Shaked,
Jennifer Alami,
Daniel Dumont,
Avi Stein,
Nathan Karin
Publication year - 2010
Publication title -
the journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.737
H-Index - 372
eISSN - 1550-6606
pISSN - 0022-1767
DOI - 10.4049/jimmunol.1090025
Subject(s) - ccl2 , prostate cancer , cancer research , cancer , medicine , immunology , chemokine , immune system
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom